NAA 004

Drug Profile

NAA 004

Alternative Names: Apaza™

Latest Information Update: 10 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 30 Jun 2004 Nobex has completed a phase I/II trial in Inflammatory bowel disease in USA
  • 09 Jun 2004 Phase-I/II clinical trials in Inflammatory bowel disease in USA (PO)
  • 02 Oct 2003 Clinical data from a media release have been added to the adverse events and Inflammatory Bowel Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top